And The Winner Is… Biotech Products Will Steal Top Drug Sales Spots In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The six best-selling drugs will all be biotech products, with Roche’s Avastin and Abbott’s Humira in the lead, new report says.
You may also be interested in...
Roche Checks Wallet As Important Avastin Trial Flops
After months of anticipation, Roche announced the results of a closely watched clinical trial showing that its Avastin (bevacizumab) medication failed to prevent the recurrence of early-stage colon cancer in patients who underwent surgery
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.